Pharma Research & Development, GlaxoSmithKline, Upper Providence, PA, USA.
Pharma Research & Development, GlaxoSmithKline, Upper Providence, PA, USA.
J Pharm Biomed Anal. 2019 Apr 15;167:1-6. doi: 10.1016/j.jpba.2019.01.028. Epub 2019 Jan 17.
This manuscript presents a novel methodology for calculating the relative response factors (RRFs) of unstable degradation impurities of molibresib (1). The degradation impurities were observed by HPLC during stress testing and were accompanied by large mass balance deficits. However, the impurities could not be isolated for traditional RRF determination due to their instability. The RRFs of two degradation impurities were determined without isolation by multiple linear regression analysis of HPLC-UV data. The results permitted accurate quantification of the degradants. The benefits and drawbacks of the approach are discussed, including suggested validation acceptance criteria.
本文提出了一种计算不稳定降解杂质相对响应因子(RRF)的新方法,用于莫利布昔布(1)。在稳定性试验中通过 HPLC 观察到降解杂质,并且伴随着大量的质量平衡亏损。然而,由于这些杂质的不稳定性,无法进行传统的 RRF 测定而对其进行分离。通过 HPLC-UV 数据的多元线性回归分析,无需分离即可确定两种降解杂质的 RRF。该方法可准确量化降解产物。讨论了该方法的优缺点,包括建议的验证验收标准。